Fierce Biotech April 17, 2024
Ultimovacs previously hinted at a dash to preserve cash following the failure of its cancer vaccine in a phase 2 trial. Now, the Norwegian biotech has revealed that 40% of staff will be jettisoned to keep the company afloat next year.
Ultimovacs had been assessing the effect of adding UV1, a candidate designed to induce a T-cell response against an enzyme that is active in most cancer cells, to Bristol Myers Squibb’s checkpoint inhibitors Opdivo and Yervoy. But the long-awaited results in March revealed the study in melanoma failed to hit either the primary endpoint of progression-free survival or secondary endpoints like overall survival and objective response rate.
In a presentation to investors this morning, execs confirmed that an analysis...
Today's Sponsors
Today's Sponsor